摘要
基于精神分裂症的谷氨酸功能紊乱假说,实验用N-甲基-D-天门冬氨酸(NMDA)非竞争性受体拮抗剂MK801(5-甲基二氢二苯并环庚稀亚氨马来酸或地卓西平马来酸盐)作用于实验小鼠,观察到类似精神分裂症的症状:移动加快(hyperloeomotion)和刻板性动作(stereotypy),建立了可用仪器测定的两项量化指标。根据作用于近交系BALB/c小鼠的MK801的剂量优化结果,用0.6 mg/kg体重的MK801剂量初步建立了精神分裂症小鼠模型,并用近交系C57BL/6小鼠成功重复了上述实验。进一步用系列剂量的MK801作用于远交群ICR小鼠,同样也诱发了类似精神分裂症的症状。用目前临床上常用的抗精神分裂症药物利培酮作用于已建立的BALB/c小鼠和C57BL/6小鼠的精神分裂症模型,结果表明利培酮能显著地抑制两品系模型小鼠的类似精神分裂症的症状。实验结果证明:用MK801作用于实验小鼠建立精神分裂症动物模型是可行的。
Based on the glutamate dysfunction hypothesis for the pathophysiology of schizophrenia, MK801, a noncompetitive antagonist for the NMDA-type of glutamate receptors, was administered to mice by i.p. injection. We observed hyperlocomotion and stereotypy, two behavioral signs indicative of schizophrenic symptoms in human. Aided with automated movement measuring of locomotion and videotaping for off-line scoring of stereotypy, these two schizophrenia-like behaviors were readily evaluated. According to the result of dose-response measurements of serial MK801 dosages in the BALB/c inbred mice, 0.6 mg/kg MK801 was determined as the optimum dosage for these behaviors. Furthermore, the same experiments were performed in another inbred strain C57BL/6 and the outbred stock ICR, and similar results were obtained. These results show that MK801 induces schizophrenia-like symptoms in beth inbred and outbred mice. Risperidone, an atypical antipsychotic drug for treating schizophrenia in human, was used in the schizophrenia models using BALB/c and C57BL/6 mice. The results indicated that risperidone dose-dependently inhibited the MK801-induced schizophrenia-like symptoms in BALB/c and C57BL/6 mice. Thus, our results indicate that the MK801-induced behaviors may serve as useful mouse models of schizophrenia.
出处
《生理学报》
CAS
CSCD
北大核心
2003年第4期381-387,共7页
Acta Physiologica Sinica
基金
This work was supported by the National Natural Science Foundation of China (No. 30270219).
